Skip to content

Serial Phlebotomy in Voluntary Blood Donors

Serial Phlebotomy in Voluntary Blood Donors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02762422
Enrollment
84
Registered
2016-05-05
Start date
2009-06-30
Completion date
2012-08-31
Last updated
2016-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

endothelial function, iron stores, red blood cell, blood donation

Brief summary

Blood donation has been proposed to be associated with reduced risk of cardiovascular disease, but the effects of phlebotomy on vascular function in human subjects have not been well characterized. A prospective randomized double-blind study was undertaken to determine the effects of iron loss and red blood cell loss induced by serial phlebotomy on vascular endothelial function in the brachial artery.

Detailed description

84 Fe-replete, non-anemic subjects were randomly assigned to one of three experimental serial phlebotomy procedures designed to induce Fe loss or RBC loss. Brachial artery reactivity (BAR, %) in response to transient oxidative stress induced by oral methionine was measured with high-resolution duplex ultrasound imaging before and after study phlebotomy procedures.

Interventions

OTHERPhlebotomy

Removal of 500 cc of blood via forearm vein

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
National Center for Research Resources (NCRR)
CollaboratorNIH
NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* hemoglobin levels \>13.5 g/dl for men, or \>12.5 g/dl for women * serum ferritin 50-400 ng/ml

Exclusion criteria

* known intolerance of phlebotomy procedures * major trauma or surgical procedures in the last 2 years * menstrual or other uterine bleeding in the last 2 years * chronic oral anticoagulation or dual antiplatelet therapy * chronic non-steroidal anti-inflammatory drug use * known history of hemochromatosis or other disorder of hematopoiesis or Fe metabolism * chronic oral Fe supplementation other than Fe-containing multivitamins * history of active cancer in the past 2 years * known history of chronic inflammatory disease * uncontrolled hypertension * electrocardiographic evidence of prior myocardial infarction * diabetes mellitus * fasting glucose \>100 mg/dL * body mass index \>40 kg/m2 * any tobacco use in the past 6 months

Design outcomes

Primary

MeasureTime frameDescription
Brachial artery reactivity response to oral methionine administrationBefore and 1 week after completion of assigned phlebotomy proceduresMeasure by vascular ultrasound imaging

Secondary

MeasureTime frameDescription
Iron deficiency anemiabefore each phlebotomy procedure, and at 1, 8, and 16 weeks after completion of assigned phlebotomy procedureshemoglobin level measured by hemocue or complete blood count

Other

MeasureTime frame
Serum ferritinBefore and 1 week after completion of assigned phlebotomy procedures
Serum nitrotyrosineBefore and 1 week after completion of assigned phlebotomy procedures
Whole blood viscosityBefore and 1 week after completion of assigned phlebotomy procedures

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026